Anaptysbio (ANAB) Cash & Current Investments (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Cash & Current Investments data on file, last reported at $286.5 million in Q1 2026.

• Quarterly Cash & Current Investments fell 15.73% year-over-year to $286.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $286.5 million (down 15.73% YoY) and the FY2025 annual result came in at $311.6 million, down 19.13% from the prior year.
• Cash & Current Investments slipped to $286.5 million in Q1 2026, from $311.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $505.6 million in Q1 2022 to a low of $249.0 million in Q3 2025.
• A 5-year average of $380.6 million and a median of $390.9 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2022 — Cash & Current Investments jumped 33.05% — and 2025, when it slumped 42.12%.
• Tracing ANAB's Cash & Current Investments over 5 years: stood at $441.2 million in 2022, then dropped by 11.41% to $390.9 million in 2023, then slipped by 1.41% to $385.4 million in 2024, then fell by 19.13% to $311.6 million in 2025, then decreased by 8.08% to $286.5 million in 2026.
• The last three Cash & Current Investments figures came in at $286.5 million (Q1 2026), $311.6 million (Q4 2025), and $249.0 million (Q3 2025), per Business Quant data.